GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Pfizer

The FDA has accepted and granted Priority Review to ViiV Healthcare's marketing application seeking approval for injectable cabotegravir long-acting for pre-exposure prophylaxis (PrEP). The priority review designation sets ViiV up for a decision from the agency by January 24, 2022.

GSK, Pfizer Backed Long-Acting HIV Med Under FDA Priority Review As Preventative Option

WARREN, N.J., Sept. 28, 2021 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) is raising a cup – or two – of coffee to celebrate enjoying life's simple pleasures without the interruption of tooth sensitivity.

Sensodyne® Repair and Protect with Deep Repair is Proud to Deliver a Minty & Whitening Toothpaste, Just in Time for National Coffee Day

GlaxoSmithKline PLC underlined its commitment to new vaccines to tackle HIV with subsidiary ViiV Healthcare agreeing to a new deal with Japanese firm Shionogi to develop an ultra-long medicine for the condition. Shionogi, alongside Pfizer, is a minority shareholder in ViiV and will receive US$20mln upfront, a possible US$15mln in milestone payments and royalties on net sales.

GlaxoSmithKline strengthens HIV pipeline with new Japanese deal

Vir Biotechnology

Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19 antibody therapy. Related Link:   GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients.

Glaxo - Vir Biotech's COVID Treatment Approved In Japan

The small activist hedge fund Bluebell Capital Partners has joined the attack on GlaxoSmithKline CEO Emma Walmsley.

Another Hedge Fund Joins in Criticism of GlaxoSmithKline CEO

GlaxoSmithKline PLC boss Emma Walmsley has a second activist to deal with on the company's shareholder register, with Bluebell Capital Partners taking a small stake and calling for change. Bluebell, flushed with recent success from its campaign at French food giant Danone, has written to GSK chairman Jonathan Symonds to demand Walmsley reapply for her job.

GlaxoSmithKline boss under pressure from second activist

Activist investor Bluebell Capital Partners has taken a small stake in British pharmaceuticals group GlaxoSmithKline in efforts to shake up top management, a Financial Times report said on Wednesday.

Activist investor Bluebell takes stake in GSK - FT

Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe

Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

Dynavax Technologies

Inovio Pharmaceuticals

Novavax

Sanofi

Their vaccines could be late to the party. But the stocks might still be big winners.

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

Artificial intelligence will be used to develop personalised treatments while investigating role of genetics

GSK teams with King's College to use AI to fight cancer

The respected London healthcare team of Wall Street research house Jefferies has delivered a bitter-sweet update to coverage of GlaxoSmithKline PLC. While it has tweaked down its revenue forecast for the third quarter, it said it remains a long-term fan of the stock.

GlaxoSmithKline shares fall, but is now the time to start buying? Here's what one Wall Street research house reckons

GlaxoSmithKline plc (GSK) Management Presents at Citi's 16th Annual BioPharma Virtual Conference (Transcript)

Johnson & Johnson

GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big pharma are also in line to be rewarded for developing a shot for respiratory syncytial virus, with Pfizer Inc. ( PFE , Financial) raking in $2.1 billion, Johnson & Johnson ( JNJ , Financial) adding $1.7 billion to its top line and Sanofi SA ( SNY , Financial) pocketing $1.2 billion.

Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business

GlaxoSmithKline (GSK) and SK bioscience begin a phase III study on GBP510, the latter's COVID-19 vaccine candidate. The study will compare GBP510 against AstraZeneca's COVID-19 vaccine.

Glaxo (GSK), SK bioscience's COVID-19 Jab Enters Phase III Study

Amazon

Aspen Technology Inc

Alibaba

Bayer AG

Baidu

British American Tobacco

Anheuser-Busch InBev

Campbell Soup

Enterprise Products Partners

Imperial Brands PLC

Intel

Kellogg

Lockheed Martin

Merck

Polaris

Reckitt Benckiser Group PLC

Roche Holding AG

Tencent Holdings Limited

Western Union

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The September 2021 Heat Map

AstraZeneca

GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The study will enroll 4,000 participants and compare the shot to Oxford University - AstraZeneca Plc (NASDAQ: AZN).

Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot

GlaxoSmithKline PLC has started phase III trials of a Covid-19 vaccine that will test itself against rival AstraZeneca PLC's jab. This study will be one of the first global Phase 3 trials to compare two different Covid-19 vaccine candidates said Glaxo, with AstraZeneca/Oxford University's Covid-19 vaccine the active comparator in the trial.

GlaxoSmithKline to test new Covid vaccine against AstraZeneca jab

Airbnb

Fastly

Jumia

NIKE

Upstart Holdings

From vaccines to video games, these stocks to buy have the most attractive long-term bull cases in their respective industries. The post The 7 Best Stocks to Buy for September appeared first on InvestorPlace.

The 7 Best Stocks to Buy for September

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the study is unlikely to meet its goal of improving overall survival. The INTR@PID BTC 055 trial examined the drug as a first-line treatment for patients with locally advanced or metastatic biliary tract cancer combined with the chemotherapy drugs cisplatin and gemcitabine.

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial

The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab, a monoclonal antibody for COVID-19. The approval covers adults and adolescents who do not require initiation of oxygen due to COVID-19 and are at increased risk of progression to hospitalization or death.

Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia

GlaxoSmithKline PLC (NYSE: GSK) traded at a new 52-week high today of $42.68. This new high was reached on below-average trading volume as 1.4 million shares traded hands, while the average 30-day volume is approximately 3.8 million shares.

GlaxoSmithKline PLC Looks To Continue To Trade Above Its Annual-High Share Price Today

The FDA grants accelerated approval to Glaxo's (GSK) Jemperli for treating patients with mismatch repair-deficient recurrent/advanced solid tumors. This is the second approved indication for the drug.

Glaxo's (GSK) Jemperli Gets FDA Approval for New Indication

Buy and hold GlaxoSmithKline Plc is far from the most radical or unique stock market call you'll see today, or any other day for that matter, nevertheless, European broker Berenberg says there's “deep value” for patient investors. Repeating a ‘buy' recommendation and upgrading its price target to £16.25 from £15.70, suggesting around 8% upside to the current price of £15.19.

GlaxoSmithKline investors set for deep value if they stay patient

GSK Next, the innovation arm of GlaxoSmithKlein, is launching a new mentorship and business development program. Called the Re/Wire Health Studio, the program will eventually select six startups who will win access to nine weeks of mentoring, business development expertise, and cash grants.

GSK and R/GA Ventures are launching a health studio for startups

Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

Genuine Parts

Huntington Bancshares

Illinois Tool Works

Leggett & Platt

Norfolk Southern

Realty Income Corp

Occidental Petroleum

Philip Morris

J. M. Smucker

Schlumberger

Scotts Miracle-Gro

T. Rowe Price Group

TotalEnergies SE

ViacomCBS

In July, we received $771.96 in dividend income! Our top dividend payment for the month was a HUGE special dividend payment from T. Rowe Price.

Dividend Income Summary: Bert's July 2021 Summary

News for GlaxoSmithKline Stock (GSK)